TO SCREEN OR NOT TO SCREEN

[ { "title": "to screen or not to screen", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/3/01.jpg", "position": "0" }, { "title": "Is there undertreatment of male hypogonadism", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/3/02.jpg", "position": "4" }, { "title": "screening for hypogonadism/androgen deficiency recommendations", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/3/03.jpg", "position": "90" }, { "title": "benefits of screening", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/3/04.jpg", "position": "220" }, { "title": "EMAS Study: evidence-based criteria identifying LOH defined", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/3/05.jpg", "position": "242" }, { "title": "screening due to comorbidities", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/3/06.jpg", "position": "342" }, { "title": "conditions with a high prevalence of testosterone levels: screening recommended", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/3/07.jpg", "position": "350" }, { "title": "screening measures", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/3/08.jpg", "position": "381" }, { "title": "Questionnaires", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/3/09.jpg", "position": "394" }, { "title": "ADAM questionnaire (1)", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/3/10.jpg", "position": "428" }, { "title": "ADAM questionnaire (2)", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/3/11.jpg", "position": "457" }, { "title": "Summary", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/3/12.jpg", "position": "472" } ]